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Endpoint
Prior
CABG
(N1133)
No prior
CABG
(N17495) HR (95% CI) p
Efficacy
Primary Outcome:
CV Death / MI
(excluding silent) /
Stroke
20.5 (216) 10.1 (1662) 2.06 (1.79, 2.38) .0001
CV
death/MI/stroke in
patients intended
for invasive
management
18.9 (131) 9.3 (1106) 2.03 (1.69, 2.43) .0001
All Cause Death /
MI (excluding
silent) / Stroke
21.4 (225) 10.6 (1741) 2.05 (1.79, 2.36) .0001
Cardiovascular
Death (includes
vascular and
unknown deaths)
7.2 (75) 4.4 (720) 1.61 (1.27, 2.04) .0001
All Cause Death 8.2 (85) 5.0 (820) 1.60 (1.28, 2.00) .0001
Myocardial
Infarction
(excluding silent)
13.8 (144) 5.9 (953) 2.39 (2.01, 2.85) .0001
Any Stent
Thrombosis
(definite, probable
or possible)
3.5 (33) 2.2 (339) 1.48 (1.04, 2.12) 0.0307
Bleeding (study
criteria)
Any major bleeding 8.4 (84) 11.6 (1806) 0.72 (0.58, 0.89) 0.0029
Coronary Procedure
Related Major
Bleeding
5.0 (51) 9.0 (1426) 0.55 (0.42, 0.73) .0001
Non-Coronary
Procedure Related
Major Bleeding
0.2 (2) 0.4 (62) 0.51 (0.12, 2.08) 0.3484
Conclusions: Prior CABG patients represent a high risk cohort for death and recurrent
cardiovascular events but have lower risk for major bleeding. A reduction in ischemic
events without increase in major bleeding occurred with ticagrelor vs. clopidogrel in prior
CABG patients, similar to the results in non-prior CABG patients.
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Background: There is still uncertainty regarding the optimal dual antiplatelet therapy
(DAPT) duration after percutaneous coronary interventions (PCI). We evaluate benefits
and risks of extending DAPT after PCI in the drug-eluting stent era.
Methods: We searched electronic databases (Medline, EMBASE, the Cochrane Central
Register of Controlled Trials), relevant websites, reference lists, conference abstracts,
reviews, chapters in books and proceedings of advisory panels for the US Food and Drug
Administration, for randomized controlled trials investigating the clinical impact of
extending DAPT duration in patients undergoing PCI. The primary endpoint was
all-cause death. The secondary endpoints were myocardial infarction (MI), stent throm-
bosis (ST), cerebrovascular accidents (CVA) and Thrombolysis in Myocardial Infarction
(TIMI) major bleeding.
Results: We included four trials which randomized 8,231 patients (50.2%, extended
DAPT duration versus 49.8%, control duration). A total of 8,158 patients (99.1%) were
available for final analyses. Median DAPT duration was 16.8 versus 6.2 months for the
extended DAPT and control groups, respectively. At follow-up (median 16.8 months)
extending DAPT duration did not reduce all-cause death (odds ratio [95% confidence
interval]  1.15 [0.85-1.54], p0.36), MI (0.95 [0.66-1.36], p0.77), ST (0.88 [0.43-
1.81], p0.73) or CVA (1.51 [0.92-2.47], p0.10). Conversely, extended DAPT duration
clearly increased the risk of TIMI major bleeding (2.64 [1.31-5.30], p0.006).
Conclusions: Extending dual antiplatelet therapy duration after percutaneous coronary
interventions increased the risk of bleeding without reducing the incidence of death,
myocardial infarction, stent thrombosis or cerebrovascular accidents.
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Background: In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor
significantly reduced the risk of thrombotic events compared to clopidogrel in patients
with acute coronary syndromes (ACS). We aimed to investigate whether clinical
presentation (STEMI vs. NSTE-ACS) has any interaction with platelet inhibition between
ticagrelor and clopidogrel.
Methods: In a non-prespecified, single-center, pharmacodynamic analysis of the PLATO
randomized, blinded, placebo-controlled trial, platelet inhibition was compared in patients
randomized to clopidogrel (n55) or ticagrelor (n53) at 24-48 hours of receiving
loading doses (LD) and during the maintenance period (7 days) of treatment. Maximal
platelet aggregation (MPA) was measured with light transmission aggregometry using ADP
5 M. P values for interaction between STEMI and NSTE-ACS were calculated regarding
mean MPA and for the odds of high platelet reactivity (HPR, defined as MPA46%).
Results: In 77(71.3%) patients with STEMI and 31(28.7%) with NSTE-ACS, 94 loading
phase and 150 maintenance phase measurements were performed. Both after the LD and
MD, patients on ticagrelor showed significantly lower MPA values compared to
clopidogrel without any interaction between STEMI and NSTE-ACS (p for interaction:
0.33 and 0.28 after LD and MD, respectively; Table 1) In line with these findings, patients
randomized to ticagrelor experienced a huge reduction in the odds for HPR regardless of the
clinical presentation (p for interaction: 1.00 and 0.30 after LD and MD, respectively; Table 1).
Mean difference
in MPA
(ticagrelor-
clopidogrel, %) 95% CI P interaction
After loading dose
STEMI 27.67 34.19; 21.15 0.30
NSTE-ACS 32.85 41.05;24.65
During maintenance
dose
STEMI 15.93 22.01; 9.85 0.28
NSTE-ACS 21.91 30.79;13.03
Odds ratio for
HPR (ticagrelor
vs. clopidogrel) 95% CI
P
interaction
After loading dose
STEMI 0.02 0.00; 0.20 1.00
NSTE-ACS 0.02 0.00; 0.54
During maintenance
dose
STEMI 0.12 0.04; 0.39 0.30
NSTE-ACS 0.02 0.00; 0.44
Conclusions: MPA values and the rate of HPR were largely and significantly reduced in
patients randomized to ticagrelor both after LD and MD, regardless of the clinical
presentation. This post-hoc, single-center, pharmacodynamic analysis of the PLATO trial
suggest no attenuation of platelet inhibition in patients presenting with STEMI compared
to those with NSTE-ACS.
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Background: Twelve months duration of dual antiplatelet therapy (DAPT) after
implantation of a drug-eluting stent (DES) is recommended to decrease risk of stent
thrombosis (ST). Controversies surround the optimal duration of DAPT for reducing risk
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